Fasturtec

Fasturtec Caution For Usage

rasburicase

Manufacturer:

Sanofi

Distributor:

DCH Auriga - Healthcare
/
Four Star
Full Prescribing Info
Caution For Usage
Instructions for Use/Handling and Disposal: Rasburicase must be reconstituted with the solvent supplied and further diluted only in 9 mg/mL sodium chloride IV solution (0.9% w/v).
Reconstitution: Add the contents of 1 amp of solvent to 1 vial containing rasburicase and mix by swirling very gently under controlled and validated aseptic conditions.
Do not shake.
Inspect visually prior to use. Only clear solutions without particles should be used.
For single use only, any unused solution should be discarded.
The solvent contains no preservative. Therefore, the reconstituted solution should be diluted under controlled and validated aseptic conditions.
Dilution Before Infusion: The required quantity of solution (according to the patient's body weight) is to be further diluted with 9 mg/mL sodium chloride solution (0.9% w/v) to make up a total volume of 50 mL. The reconstituted solution contains no preservative. Therefore, the diluted solution should be infused immediately.
Infusion: The final solution should be infused over 30 min.
Sample Handling: If it is necessary to monitor a patient's uric acid level, a strict sample handling procedure must be followed to minimize ex vivo degradation of the analyte. Blood must be collected into pre-chilled tubes containing heparin anticoagulant. Samples must be immersed in an ice/water bath. Plasma samples should be immediately prepared by centrifugation in a pre-cooled centrifuge 4°C. Finally, plasma must be maintained in an ice/water bath and analysed for uric acid within 4 hrs.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in